NRX | Jotup

NurExone Appoints Dr. Reuter Investor Relations in Europe

Retrieved on:

Thursday, September 28, 2023

Agreement, TSX Venture Exchange, Acceleration, CAD, FSE, NRX, Warrant, Amendment, Patient, CFO, Security (finance)

Reuter”) to assist with investor relations and financial publication services for the European capital markets.

Key Points:

Reuter”) to assist with investor relations and financial publication services for the European capital markets.
The investor relations work focuses primarily on financial press releases in German-speaking countries (Germany, Austria and Switzerland).
Dr. Reuter Investor Relations, located in Frankfurt, Germany, has been active in the market since 2006.
The company specializes in the European capital markets and offers services in the areas of financial press releases, institutional investor relations and retail investor relations.

NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug

Retrieved on:

Wednesday, September 13, 2023

Communication, Tetraplegia, Drug discovery, Clinical trial, FSE, NRX, Regeneration, Patient, Exosome, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

TORONTO and HAIFA, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is pleased to announce that the Company has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first ExoTherapy product, after receiving a written response from the FDA on August 29, 2023.

Key Points:

The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required.
The completed Pre-IND meeting with the FDA is expected to expedite NurExone’s regulatory process to initiate Phase 1/2 human clinical studies in 2025.
A Pre-IND meeting offers open communication between applicants and the FDA, enabling the applicants to receive information regarding the preparation of an IND application and guidance for the clinical studies of the Company’s ExoPTEN drug.
The drug is being developed using NurExone’s proprietary ExoTherapy platform for producing and loading exosomes with pharmaceutical cargo targeting central nervous system injuries.

NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M

Retrieved on:

Wednesday, September 6, 2023

Indian stock exchange, TSX Venture Exchange, Private placement, Private, Placement, CAD, Unit, FSE, Person, NRX, Regulation, Trust, Patient, Warrant, CFO, News, Security (finance)

An aggregate of 750,000 units of the Company (each a “Unit”) were issued and sold under the Second Tranche at a price of CAD$0.275 per Unit for aggregate proceeds of CAD$206,250.

Key Points:

An aggregate of 750,000 units of the Company (each a “Unit”) were issued and sold under the Second Tranche at a price of CAD$0.275 per Unit for aggregate proceeds of CAD$206,250.
In the aggregate, the Company issued and sold 5,394,548 Units at a price of CAD$0.275 per Unit for aggregate proceeds of CAD$1,483,500.70 under the Private Placement.
All securities issued under the first and Second Tranche are subject to a statutory hold period of four months and one day from the closing of the Second Tranche.
Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S.

NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on:

Monday, August 28, 2023

Research and development expenses were US$0.46 million in the second quarter of 2023, compared to US$0.30 million in the same quarter in 2022.

Key Points:

Research and development expenses were US$0.46 million in the second quarter of 2023, compared to US$0.30 million in the same quarter in 2022.
There were no listing expenses incurred in the second quarter of 2023, compared to US$2.04 million in the second quarter of 2022.
Financial (income) expenses were (US$0.02) million in the second quarter of 2023, compared to US$0.28 million in the same period in 2022.
Net loss was US$1.04 million in the second quarter of 2023, compared to a net loss of US$3.80 million in the second quarter of 2022.

NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery

Retrieved on:

Thursday, July 20, 2023

TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality.

Key Points:

TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality.
Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality.
Through state-of-the-art production methodologies, NurExone aims to unlock the full potential of EVs as powerful therapeutic tools.
This is critical to ensure targeted delivery of therapeutic cargo to specific cell types, maximizing the potential of EVs as drug delivery vehicles.

Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®

Retrieved on:

Thursday, July 13, 2023

Insurance, TRX, PALO, Prescription, Pain, PHN, Patient, OTC, Growth, NRX, Therapy, Chronic pain, YTD, Safety, Neurology, Pharmaceutical industry

Neurologists and HCPs estimate that they will prescribe ZTlido® to 64% of their patients in cases where they are using market leading neuropathic pain products.

Key Points:

Neurologists and HCPs estimate that they will prescribe ZTlido® to 64% of their patients in cases where they are using market leading neuropathic pain products.
1
Unlike conventional lidocaine patches, ZTlido® utilizes ZTech technology—an advanced adhesion and delivery system designed for a lidocaine patch, allowing it to efficiently deliver 12 hours of pain relief for patients.
ZTlido® new prescriptions (NRxs) grew by 34% and total prescriptions (TRxs) grew by 27% in YTD Q2-2023, compared to Q2-2022.
NRxs grew by 38% and TRxs grew by 31% in YTD Q2-2023, compared to YTD 2022.

Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN

Retrieved on:

Thursday, June 22, 2023

The image analysis and measurements confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats.

Key Points:

The image analysis and measurements confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats.
Subsequently, the spinal cords of rats from the study were subjected to advanced Diffusion Tensor Imaging (DTI) to assess the structural integrity of the spinal cord.
ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI) administrated intranasally and yielding neuron regeneration and rewiring in traumatically damaged spinal cords.
These DTI tractography images and measurements indicate re-innervation and nourishment to the caudal spinal cords in ExoPTEN rats treated intranasally.

NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device

Retrieved on:

Thursday, June 1, 2023

NTA, Central nervous system, Nanoparticle tracking analysis, Administration, Fluorescence, Exosome, FSE, NRX, TEL, Patient, Quality control, Zeta potential, Knowledge, The Company, Medical device

In connection with the collaboration, a highly-advanced Nanoparticle Tracking Analysis instrument ("NTA") has been recently placed.

Key Points:

In connection with the collaboration, a highly-advanced Nanoparticle Tracking Analysis instrument ("NTA") has been recently placed.
At NurExone’s laboratory, which is an important milestone in the expansion of NurExone’s production and analytic processes.
The newly acquired NTA, which is the first of its kind in Israel, is equipped with state-of-the-art capabilities including nanoparticle tracking analysis and advanced colocalization technology.
The new system is a ZetaView TWIN Laser System PMX-230 using wavelengths of 520 and 640 nanometers for size, concentration, fluorescence, colocalization and Zeta Potential analysis.

NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on:

Wednesday, May 24, 2023

As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.

Key Points:

As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.
Research and development expenses were US$0.37 million in the first quarter of 2023, compared to US$0.28 million in the same quarter in 2022.
Financial (income) expenses were (US$0.01) million in the first quarter of 2023, compared to US$0.09 million in the same period in 2022.
Net loss was US$0.70 million in the first quarter of 2023, compared to a net loss of US$2.31 million in the first quarter of 2022.

NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries

Retrieved on:

Tuesday, May 16, 2023

Patent, Technion – Israel Institute of Technology, Intellectual property, United States Patent and Trademark Office, Exosome, Tel Aviv University, FSE, 1836 U.S. Patent Office fire, DSM-IV codes, Doctor of Philosophy, NRX, Central nervous system, Technology Development Foundation of Turkey, TEL, Patient, Child, Invention, The Company, Pharmaceutical industry

The patent protects NurExone’s Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.

Key Points:

The patent protects NurExone’s Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.
Both Technology transfer companies, Technion Research and Development Foundation Ltd. and Ramot at Tel Aviv University Ltd are the assignees on the granted patent.
“We are pleased to have been granted a patent for our propriety drug product, Exo-PTEN,” said Dr. Lior Shaltiel, CEO of NurExone.
“The latest patent expands our intellectual property portfolio and enables us to be the exclusive provider of this unique exosome-based therapy that is designed to treat acute spinal cord injuries.”